There are large individual differences among humans and animals in behavioral, physiological and toxicological responses to drugs of abuse. Many of these individual differences in behavioral responses to drugs display substantial genetic components. Transgenic animals provide means for approaching three interrelated goals: 1)Ascertainment of biochemical and behavioral consequences of the introduction of or disruption of specific genes; 2)Ascertainment of the consequences of overexpressing candidate genomic regions identified in human tudies; 3) Elucidation of gene elements yielding cell-type specific expression and trans-synaptic gene regulation. Dopaminergic systems' involvement in central mechanisms of reward and reinforcement, and involvement of pre- and post-synaptic opioid peptide systems in the effects of opiate drugs has led to continuing focus on these systems during this year. Previoiusly-reported failure to reduce cocaine reward in DAT, SERT or NET knockout mice has led to expanded efforts to study combined transporter knockouts. Each of these assessments has provided novel data concerning the relationship between expression of each of these gene products at normal levels and drug-induced behavioral changes. In particular, studies of mice without combinations of DAT, VMAT2, SERT, NET and/or dopamine and serotonin receptor subtypes provides striking evidence for mechanisms of cocaine and amphetamine reward, monoaminergic involvement in mechanisms of sleep/wake regulation, and apparent monoamine transporter involvement in cocaine's aversive properties. Combined transporter deletions can thus either substantially enhance cocaine reward or substantially reduce it, as measured in conditioned place preference paradigms. DAT knockouts can complement the cocaine reward alterations induced by 5HT1B knockout. However, 5HT1B heterozygous deletions can comlement the loss of cocaine-stimulated locomotor activity in the DAT knockout snimals. Normally-nonrewarding selective NET and SERT blockers gain rewarding properties in mice with deletions of other monoaminergic transporters. DAT- and SERT- knockout mice display specific, striking sleep phenotypes. Studies of the first of the candidate genes identified in human positional cloning studies, BDNF, provide a striking reduction in cocaine reward in heterozygous BDNF knockout mice that are subject of only modest disability in other spheres. These studies contribute to a novel models for combined rewarding and aversive properties of psychostimulants further developed in the Branch during this year. They also provid evidence for selective serotonin receptor involvment in the neuroadaptations that render cocaine an ineffective locomotor stimulant in the DAT knockout mice.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000165-07
Application #
6680328
Study Section
(MNRB)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2002
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Uhl, George R; Drgonova, Jana; Hall, F Scott (2014) Curious cases: Altered dose-response relationships in addiction genetics. Pharmacol Ther 141:335-46
Kitanaka, Nobue; Kitanaka, Junichi; Hall, F Scott et al. (2008) Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal. Synapse 62:689-99
Ide, Soichiro; Minami, Masabumi; Ishihara, Kumatoshi et al. (2008) Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in micro-opioid receptor knockout mice. Neuropharmacology 54:1182-8
Perona, Maria T G; Waters, Shonna; Hall, Frank Scott et al. (2008) Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 19:566-74
Onaivi, Emmanuel S; Ishiguro, Hiroki; Gong, Jian-Ping et al. (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 3:e1640
Uhl, George R; Drgon, Tomas; Johnson, Catherine et al. (2008) ""Higher order"" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol 75:98-111
Seeman, Philip; Hall, Frank Scott; Uhl, George (2007) Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61:573-6
Fukushima, Setsu; Shen, Haowei; Hata, Harumi et al. (2007) Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193:55-62
Yamamoto, Hideko; Kamegaya, Etsuko; Hagino, Yoko et al. (2007) Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem Int 51:237-44
Uhl, George (2007) Premature poking: impulsivity, cocaine and dopamine. Nat Med 13:413-4

Showing the most recent 10 out of 47 publications